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Cardiac transplantation was car-
ried out on four patients at the 
Medical College of Virginia be-
tween May and October of 1968, 
in an effort to salvage them from 
the terminal stages of otherwise 
uncorrectable heart disease. Despite 
a strikingly good early recovery 
from operation in each case, three 
of the patients died of acute homo-
graft rejection in one to three 
weeks; our second case is living and 
well, ten months after operation, 
and is at this writing the world's 
third longest survivor. The world 
experience to June of 1969 includes 
about 130 cardiac transplants. Of 
the first 100 patients operated on 
over six months ago, 20 are sur-
viving, and the majority of these 
have returned to a productive exist-
ence, demonstrating the feasibility 
of complete rehabilitation of at least 
some terminal patients after car-
diac transplantation. The high mor-
tality rate-significantly higher than 
was anticipated-has resulted from 
acute and chronic homograft re-
jection and from the equally dif-
ficult problem of infection. Certain 
lessons have been learned from our 
own experience and from the world 
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experience with this procedure, and 
these will be reviewed in an at-
tempt to establish the current status 
and future potential of cardiac 
transplantation. 
Background: Animal 
Experimentation 
The information gained from ten 
years of our laboratory experience 
in part set the stage for the clinical 
trials of cardiac transplantation ini-
tiated by Barnard in December of 
1967. These investigations were be-
gun first in the laboratories of Dr. 
Norman E. Shumway of Stanford 
University and later continued at 
the Medical College of Virginia. 
The feasibility of the procedure was 
first established in December of 
1959 when dogs were shown to re-
cover completely after orthotopic 
homotransplantation of the heart 
(Lower and Shumway, 1960; 
Lower, Stofer and Shumway, 1961). 
The animals lived from 4 to 21 
days without immunosuppressive 
therapy and exhibited remarkably 
normal activity until death from 
rejection supervened, providing 
convincing evidence that the trans-
planted heart could recover excel-
lent function despite the interrup-
tion of nerves and lymphatics. In 
a subsequent study two dogs recov-
ered after transplantation of the 
heart and both lungs (Lower et al., 
1961). The animals died after five 
days, but showed normal ventila-
tion and gas exchange prior to the 
onset of rejection. 
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Further laboratory studies 
(Lower, Dong and Shumway, 
1965a,b; Lower, Dong and Glaze-
ner, 1966) revealed that the most 
sensitive and reliable test for im-
pending cardiac rejection was a fall 
in the QRS voltage on the electro-
cardiogram, often with the addi-
tional finding of abnormal intra-
ventricular conduction. With the 
advent of immunosuppressive 
drugs, specifically azathioprine and 
methylprednisolone, survival of ani-
mals was prolonged by treating 
each recognized rejection crisis 
with transiently high doses of the 
drugs which were then tapered to 
lower maintenance doses in an at-
tempt to diminish the high inci-
dence of toxicity and infection. A 
few animals survived more than a 
year and provided a significant 
stimulus to the subsequent clinical 
application of cardiac transplanta-
tion. Extensive physiologic tests of 
the transplanted heart revealed that, 
although function was often de-
pressed for the first 24 to 48 hours, 
thereafter cardiac output, even in 
response to stress, was remarkably 
adequate (Dong et al., 1965). In 
some animals made to breathe 7 % 
oxygen, cardiac outputs could be 
markedly increased (Kontos and 
Lower, 1969). 
Evidence of autonomic reinner-
vation was seen in the majority of 
transplants within a few months af-
ter operation and was confirmed 
by appropriate immediate responses 
to direct electrical stimulation of 
vagal and sympathetic nerves 
(H. A. Kontos, M. D. Thames 
and R. R. Lower, unpublished 
data). The return of sinus arrhyth-
mia was also seen as a useful in-
dicator of vagal reinnervation 
(Thames, Kontos and Lower, 
1969), and the ability of the heart 
to respond reflexly to peripheral hy-
pertension also reappeared (H. A. 
Kontos et al., unpublished data). 
Recently, fluorescent staining of 
sympathetic fibers has confirmed 
their regeneration within the graft 
after several months.+ 
Although these observations fos-
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tered considerable enthusiasm con-
cerning the application of cardiac 
transplantation to human disease, 
this enthusiasm was tempered by 
certain additional observations. In 
about 25 % to 30 % of acute rejec-
tion crises, it was difficult or impos-
sible to control the rejection pro-
cess with drugs. Where continuous 
or high dose immunosuppression 
was needed, infection was often in-
evitable. Moreover, on histologic 
examination of animals surviving 
over three months, all showed some 
evidence of compromise of cor-
onary arterial lumens by thicken-
ing of the intimal layer. In some 
of the longest surviving cases a few 
of the coronary arteries were nearly 
occluded. These findings were pre-
sented in 1967 (Lower and Cleve-
land, 1968), but it was out hope 
that improved methods of histo-
compatibility matching along with 
better drugs for immunosuppres-
sion, such as antilymphocyte glob-
ulin, might make cardiac trans-
plantation in man less susceptible 
to both acute and chronic rejec-
tion. Unfortunately these aims have 
not been entirely realized. 
Selection of Recipients 
and Donors 
The selection of patients for 
cardiac transplantation has gener-
ally been reserved for those in the 
terminal stage of their illness with 
no alternative hope for recovery. 
This policy is attested to by the 
large numbers of patients who have 
died in our hospital and elsewhere 
while awaiting a suitable heart 
donor. In the Stanford series, for 
example, the mean survival of pa-
tients accepted for transplantation, 
but for whom no suitable donor 
could be obtained, has been four 
weeks, with a maximal survival of 
12 weeks (N. E. Shumway, per-
sonal communication). 
:j: Studies performed by Dr. John E. 
Norvell, Department of Anatomy, 
Medical College of Virginia. 
Two of our patients had sus-
tained multiple myocardial infarc-
tions with the subsequent develop-
ment of refractory heart failure. 
The other two patients had cardio-
myopathy of undetermined etiology 
with severe biventricular failure. 
Cardiac catheterization in each case 
revealed pulmonary hypertension, 
elevation of the left ventricular end 
diastolic pressure, low cardiac out-
put and extremely poor contractil-
ity of the left ventricle. The patients 
were all considered to have no al-
ternative hope for recovery from 
their cardiac disease and were, 
therefore, accepted for cardiac 
transplantation. 
The selection of donors required 
the establishment of irretrievable 
brain death by an independent 
team of neurosurgeons and neurol-
ogists. Brain death in these cases 
was caused by extensive intracere-
bral hemorrhage or by massive 
brain trauma. The criteria included 
no pupillary reaction, absence of 
spontaneous respiration or move-
ments, absence of reflexes and an 
isoelectric electroencephalogram. 
The heart in the donor invariably 
required vasopressors for support 
and had usually sustained one or 
more episodes of arrest. It is of 
interest that, despite its failing 
status in the donor, the heart in 
each case adequately supported the 
circulation in the recipient as soon 
as coronary blood flow was reestab-
lished. 
Prospective histocompatibility 
typing by the microlymphocyto-
toxicity techniques of Terasaki was 
carried out in each case. However, 
despite an excellent match with no 
demonstrable major incompatibility 
in the first case, the patient died of 
acute fulminating rejection at one 
week and was the first patient in 
the world experience to die from 
this cause. The course in this pa-
tient illustrated that typing, as cur-
rent y practised, does not in fact 
detect, with sufficient sensitivity, 
all forms of incompatibility. The 
second patient, however, was also 
an excellent match; and, although 
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he has sustained three rejection epi-
sodes, each one responded well to 
a temporary increase in immuno-
suppressive therapy, and he re-
mains well. 
The third patient in this series 
demonstrated a principle which 
may continue to receive increased 
attention in the preoperative match-
ings of potential recipients. Despite 
the absence of preformed anti-
bodies detected by the routine pre-
operative serum-lymphocyte cross 
match, retrospective studies of the 
patient's serum by the technique of 
immune adherence established that 
some degree of prior sensitization 
did exist, as antibodies were present 
against cultured kidney cells from 
the same donor. The patient's clini-
cal course was characterized by a 
fulminating rejection episode at one 
week which was unresponsive to 
massive immunosuppressive ther-
apy. The fourth patient, mis-
matched for histocompatibility an-
tigen HLA-3, initially responded to 
therapy for a rejection episode at 
one week, but subsequently became 
refractory to treatment and died of 
rejection at 18 days. Antibody was 
eluted from the heart postmortem 
in each of the three fatal cases. The 
possible role of antibody in acute 
cardiac rejection has been discussed 
further in another report (G. M. 
Williams et al., unpublished data). 
Surgical Techniq ue 
The basic surgical technique 
which proved successful in animal 
transplantation (Lower et al., 
1961) was employed in our own 
cases and has been generally utilized 
by other transplant surgeons with 
few modifications. The posterior 
atrial wall, containing the openings 
of the vena cavae and pulmonary 
veins, is retained in the recipient to 
facilitate anastomosis of the donor 
heart. Anastomosis of the aorta 
and pulmonary artery in the supra-
valvular region completes the pro-
cedure. Surgeons have varied most 
in their management of the donor 
heart. In our own cases the donor 
heart was cooled by immersion in 
saline at 8 to 10 C to afford the 
myocardium protection during the 
60 to 90 minutes that coronary cir-
culation was interrupted and no 
coronary perfusion was used. 
Postoperative Management 
Postoperative management of the 
recipient has varied little from the 
care of the routine cardiac surgery 
patient with the exceptions that im-
munosuppressive therapy is admin-
istered in an effort to prevent rejec-
tion, and monitoring efforts are 
directed toward the early detection 
of a rejection crisis (Lower et al., 
1968; Sewell, Kemp and Lower, 
1969). It now seems apparent that 
the cardiac transplant recipient has 
an immunologic capability that is 
less impaired than the chronically 
uremic renal transplant patient, and 
the cardiac patient, therefore, re-
quires more intensive immunosup-
pression, at least in the initial weeks, 
to control rejection. This was not 
appreciated early in our experience 
but has evolved as the world results 
have been discussed. The current 
recommendations which have re-
ceived widest acceptance are that 
the recipient be given azathioprine 
in the largest dose tolerated, usually 
3 to 4 mg/ kg, and prednisone in a 
dose of 200 mg/ day during the 
initial two to three weeks. Drugs 
are later tapered to a lower main-
tenance dose to decrease the risk of 
infection and the other side effects 
of steroid administration. 
The role of antilymphocyte glob-
ulin is less clearly established. Some 
patients have been managed suc-
cessfully without it; others have de-
veloped fatal, acute or chronic re-
jection despite its use. The optimal 
preparation, route of administra-
tion and dose have not been agreed 
upon. Some patients reportedly 
have rapidly developed antibodies 
against the horse globulin with evi-
dence that its immunologic effec-
tiveness is rapidly dissipated (But-
ler et al., 1969). A few investiga-
tors have therefore considered it 
most useful in the treatment of a 
difficult rejection crisis or where 
there are wide histocompatibility 
differences. 
Early Detection of Rejection 
The early detection of a rejection 
crisis requires close monitoring of 
the electrocardiogram on at least a 
daily basis for the first few months. 
The primary signs of impending 
rejection are a decrease in the QRS 
voltage, a rightward shift in the 
frontal plane axis, delayed intraven-
tricular conduction and atrial or 
nodal arrhythmias. Rejection is 
characterized clinically by the in-
sidious onset of right heart failure 
as evidenced by weight gain, edema, 
venous distention with increased 
pulsations, right ventricular gallop, 
and, eventually, the development of 
murmurs of relative tricuspid or 
mitral insufficiency. Early in the 
course of rejection the lung fields 
appear radiographically clear and 
even oligemic, in reflecting the pre-
dominant right heart failure. Thus, 
it is suggested that digitalis prepa-
rations and diuretics be discon-
tinued as soon as is practical after 
operation to avoid masking this im-
portant collateral evidence of im-
pending rejection. 
While serum enzyme abnormali-
ties do occur with some rejection 
episodes (particularly elevation of 
the lactic dehydrogenase isozymes I 
and II and the creatine phosphoki-
nase), these abnormalities occur as 
a late manifestation of rejection 
and indicate a more severe degree 
of myocardial injury. It is apparent 
from our own observations and the 
experience of others that a typical 
rejection crisis can occur and be 
diagnosed by other clinical and 
ECG criteria without detectable ab-
normalities in the serum enzymes. 
However, enzyme levels were 
markedly elevated in the terminal 
stages of each of the fatal rejection 
episodes in our patients. 
The other nonspecific signs and 
symptoms occurring in conjunction 
with rejection, such as pericardia! 
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friction rub, fever, leukocytosis and 
malaise, can all occur with other 
postoperative complications, e.g., 
infection, embolism or the various 
post-perfusion syndromes, and are 
thus of limited value in the diag-
nosis of impending rejection. 
Treatment of Acute Rejection 
The successful treatment of a 
rejection crisis requires the imme-
diate administration of prednisone 
in transiently high doses of 1,000 
mg daily until the clinical and car-
diographic signs of rejection im-
prove with subsequent tapering to 
maintenance levels. In addition, 
local graft irradiation, actinomycin 
and antilymphocyte globulin may 
be used. Recent laboratory studies 
in dogs with cardiac transplants 
have established by serial myocar-
dial biopsies the effectiveness of 
these measures in the treatment of 
the rejection crisis (Graham et al., 
1969). It would appear from the 
recently discussed world experience 
that about 70% of rejection crises 
can be successfully managed in this 
way. 
Yet even with successful control 
of the acute rejection problem, a 
process which has been termed 
chronic rejection may develop in 
the graft, consisting of irregular 
thickening of the intimal layer of 
the coronary arteries identical to 
that which was seen in the trans-
planted dog hearts (Lower and 
Cleveland, 1968) and in other or-
gan homografts. It is presumed that 
antigen-antibody complexes injure 
the endothelium of the vessels and 
cause agglutination and adherence 
of platelets at areas of maximum 
injury with subsequent organization 
of thrombi. Unfortunately, the de-
velopment of such lesions cannot 
be easily detected clinically, except 
perhaps by arteriography; and if 
the process goes unchecked, serious 
compromise of cardiac function 
will inevitably result. Whether pro-
phylactic antithrombotic measures 
can forestall the process until even-
tually the donor endothelium is re-
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populated by host cells has yet to 
be established. More precise histo-
compatibility matching and more 
effective immunosuppression would 
at the moment seem to offer the 
best insurance against loss of the 
graft due to chronic rejection. 
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